ArticleBlood2012
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 124 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Study of Immunotherapy With Rituximab and Pulse Dexamethasone Followed by With Mycophenolate Mofetil or Placebo in Adult Patients With Persistent and Chronic Immune Thrombocytopenia
Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy
Triple Therapy in Patients With Idiopathic Thrombocytopenic Purpura : What is Behind?
Who cites it
124 citing papers in PubMed, 5 syntheses or guidelines pooled it, 342 citations in OpenAlex.
- Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.Drug safety · 2024Pooled it
- All-trans retinoic acid added to treatment of primary immune thrombocytopenia: a systematic review and meta-analysis.Annals of hematology · 2023Pooled it
- The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.BioMed research international · 2021Pooled it
- Efficacy and safety of rituximab for minors with immune thrombocytopenia: a systematic review and meta-analysis.The Journal of international medical research · 2020Pooled it
- Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis.BioMed research international · 2018Pooled it
- Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.Annals of hematology · 2026Trial
- Safety and efficacy of daratumumab in immune thrombocytopenia.Blood advances · 2026Trial
- Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia.International journal of hematology · 2025Trial
- Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.American journal of hematology · 2019Trial
- Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.Pediatric blood & cancer · 2018Trial
- Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.International journal of hematology · 2017Trial
- A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).Blood · 2015Trial
- Trial
- Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.Haematologica · 2015Trial
- Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).Pediatric blood & cancer · 2015Trial
- Trial
- B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells.The Journal of clinical investigation · 2013Trial
- Targeting B-Cell-Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia.American journal of hematology · 2026Review
- Factors associated with response to rituximab in patients with immune thrombocytopenia.HemaSphere · 2026Article
- Successful Treatment With Rituximab for Severe Immune Thrombocytopenic Purpura During Hemodialysis.Cureus · 2026Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 5 countries.
Funding
Abstract
Treatments for immune thrombocytopenic purpura (ITP) providing durable platelet responses without continued dosing are limited. Whereas complete responses (CRs) to B-cell depletion in ITP usually last for 1 year in adults, partial responses (PRs) are less durable. Comparable data do not exist for children and 5-year outcomes are unavailable. Patients with ITP treated with rituximab who achieved CRs and PRs (platelets > 150 × 10(9)/L or 50-150 × 10(9)/L, respectively) were selected to be assessed for duration of their response; 72 adults whose response lasted at least 1 year and 66 children with response of any duration were included. Patients had baseline platelet counts < 30 × 10(9)/L; 95% had ITP of > 6 months in duration. Adults and children each had initial overall response rates of 57% and similar 5-year estimates of persisting response (21% and 26%, respectively). Children did not relapse after 2 years from initial treatment whereas adults did. Initial CR and prolonged B-cell depletion predicted sustained responses whereas prior splenectomy, age, sex, and duration of ITP did not. No novel or substantial long-term clinical toxicity was observed. In summary, 21% to 26% of adults and children with chronic ITP treated with standard-dose rituximab maintained a treatment-free response for at least 5 years without major toxicity. These results can inform clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.